Latest From Biogen Inc.
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
An SEC filing offers a fascinating insight into how Spark CEO Jeff Marrazzo and his board managed to play off a number of suitors against each other and get Roche to up its bid from $70 per share to $114.50.
Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.
- Gene Therapy, Cell Therapy
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Biogen Idec Inc.
- Biogen Inc.
- Idec Pharmaceutical Corp.
- North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
Michel Vounatsos, CEO
Jeffrey Capello, EVP, CFO
Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
Michael Ehlers, MD, PhD, EVP, R&D
Daniel Karp, EVP, Corp. Dev.
Chirfi Guindo, EVP & Head, Global Mktg.
- Contact Info
Phone: (617) 679-2000
225 Binney St.
Cambridge, MA 02142
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.